Cerulean has signed a worldwide license agreement with Calando Pharma, a subsidiary of Arrowhead Research Corporation.
Under the agreement, Cerulean has acquired worldwide rights to Calando’ proprietary cyclodextrin co-polymer-based drug delivery, to develop and commercialize therapeutic products arising from this technology.
Additionally, Cerulean has also acquired worldwide rights to develop and commercialize Calando’ clinical stage anti-cancer product candidate, IT-101. Its a camptothecin nanoparticle with a pre-clinical foundation that has just progressed through a phase-I clinical trial.
Oliver Fetzer, President and CEO, Cerulean, said: “Calando’s cyclodextrin co-polymer based technology is founded on elegant chemistry, and the integration of this platform into our program fully leverages the expertise and capabilities that we have built. We look forward to applying the technology against a range of product opportunities, as well as further advancing IT-101 in the clinic.”